Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-09-26 pm EDT
9.970 USD   -7.60%
09/23Beyond The Deal : Recursion's Transformational Partnership with Roche and Genentech
PU
09/19Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to S&P Biotechnology Select Industry Index
CI
09/16KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Recursion Pharmaceuticals: Q2 Earnings Snapshot

08/09/2022 | 05:15pm EDT

SALT LAKE CITY (AP) _ Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $65.6 million in its second quarter.

The Salt Lake City-based company said it had a loss of 38 cents per share.

The biotechnology company posted revenue of $7.7 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RXRX at https://www.zacks.com/ap/RXRX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about RECURSION PHARMACEUTICALS, INC.
09/23Beyond The Deal : Recursion's Transformational Partnership with Roche and Genentech
PU
09/19Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) adde..
CI
09/16KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target
MT
09/13Recursion Pharmaceuticals Starts Two New Clinical Trials of REC-4481, REC-3964
MT
09/13Recursion Pharmaceuticals, Inc. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
09/13Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
PR
09/13Recursion Initiates Two Additional Clinical Trials for A Total of Four in 2022
CI
09/01Recursion to Participate in Upcoming Investor Conferences
PR
08/18Insider Sell: Recursion Pharmaceuticals
MT
08/18Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs G..
PR
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 45,5 M - -
Net income 2022 -221 M - -
Net cash 2022 252 M - -
P/E ratio 2022 -6,71x
Yield 2022 -
Capitalization 1 726 M 1 726 M -
EV / Sales 2022 32,4x
EV / Sales 2023 26,9x
Nbr of Employees 400
Free-Float 84,1%
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 9,97 $
Average target price 17,00 $
Spread / Average Target 70,5%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Vice President-Software Engineering
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.-41.80%1 867
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-40.57%28 154